Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atamparib in Advanced Solid Tumors (NSCLC Adenocarcinoma)
CTR20260092Phase 2Active
- Sponsor
- Navino Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atamparib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Navino Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
atamparib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20260092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260092.